Enroll Now
You Must LOG IN to Enroll
Publication Date: 18 August 2025
Plasma-Derived Medicinal Products (PDMPs) – From Donor to Patient
Hours: 0.5
Course Description
In this lecture, Plasma Derived Medicinal Products (PDMPs) encompass a wide spectrum of therapies that play a critical role in modern healthcare, offering significant value to patients, clinicians, health systems, and society as a whole. Understanding their importance involves exploring their unique lifecycle stages, including the complex processes of plasma collection and fractionation. A comprehensive examination of PDMPs also requires a deep dive into the key challenges that affect their supply chain, spanning the entire journey “from donor to patient.” Addressing these challenges is essential to identifying and implementing effective solutions that promote more equitable and sustainable access to these vital therapies.
Course Objectives
- Explain spectrum and importance of Plasma Derived Medicinal Products (PDMPs)
- Explore value of PDMPs to patients, clinicians, health systems and society at large
- Gain insights into PDMPs unique lifecycle stages including Plasma Collection and Fractionation
- Detect key challenges across PDMPs’ supply chain “from Donor to Patient”
- Review key solutions for a more equitable and sustainable access to PDMPs
Run Time: 0.34.51
Course Instructor Bio(s)
Tomasz Kluszczynski
Founder of Aceso Healthcare & Visiting Lecturer at Warsaw University
Aceso Healthcare Consultant
Warsaw University of Technology Business School
Warsaw, Poland
Tomasz Kluszczynski is an international healthcare, pharma and HEOR expert and a visiting professor at Warsaw and Frankfurt Universities. He is the author or co-author of White Papers and articles on Patient Access, Value Based Agreements, HTA and Plasma Derived Medicinal Products (PDMPs). The latter (PDMPs) is the specific area of Tomasz’ research and expertise and he is the author of two major publications: “Socio-Economic Value of Plasma Derived Medicinal Products in Europe” in 2020 and “Appropriate Use of Immunoglobulins in Europe” in 2023. Kluszczynski has been, most recently, involved in transformative projects aimed at future-proofing healthcare systems at national and supra-national levels, such as the EU SOHO Regulation, EMA Drug Shortages Strategy, Saudi FDA Pricing Framework, Saudi MoH Rare Diseases Burden Study or the UAE Ejadah VBHC Program. Additionally, he frequently partners with patient, professional and industry associations, such as IPOPI, EPODIN, EFPIA, PhRMA or PPTA.
